Empagliflozin and Cardiac Remodelling in People Without Diabetes
The EMPA-HEART 2 CardioLink-7 Trial

Principal Investigator

Subodh Verma

MD, PhD, FRCSC

Co-Principal Investigator

C. David Mazer

MD, FRCPC

Co-Investigators

Otavio Rizzi Coelho-Filho

MD, PhD, MPH

Kim A. Connelly

MBBS, PhD, FRACP

Lawrence A. Leiter

MD, FRCPC

Hwee Teoh

PhD

Chao-Hung Wang

MD, PhD

Andrew T. Yan

MD, FRCPC

Bernard Zinman

MD, FRCPC

Collaborators

Wei-Siang Chen

Jonathan Juan

Min-Hui Liu

RN, NP, PhD

Ning-I Yang

MB ChB

The EMPA-HEART CardioLink-6 trial together with other similar trials generated considerable interest on the impact of SGLT2 inhibition on left ventricular (lower left heart) modeling in individuals living with diabetes. Given that the SGLT2 inhibitors were subsequently found to also exert benefits in populations without type 2 diabetes, the EMPA-HEART 2 CardioLink-7 clinical trial was designed to determine if the SGLT2 inhibitor empagliflozin also caused changes in left ventricular modeling in people with cardiovascular disease but without type 2 diabetes. EMPA-HEART 2 indicated that in people without type 2 diabetes, SGLT2 inhibition did not afford clinically meaningful changes in left ventricular mass. This intriguing finding was invited as a Late Breaking presentation at the 2022 AHA Annual Scientific Sessions. The full set of primary results were published in Circulation (Connelly et al. 2023)

View details on ClinicalTrials.gov

Primary Publication

Connelly KA, Mazer CD, Puar P, Teoh H, Wang C-H, Mason T, Akhavein F, Chang C-W, Liu M-H, Yang N-I, Chen W-S, Juan Y-H, Opingari E, Salyani Y, Barbour W, Pasricha A, Ahmed S, Kosmopoulos A, Verma R, Moroney M, Bakbak E, Krishnaraj A, Bhatt DL, Butler J, Kosiborod MN, Lam CSP, Hess DA, Coelho-Filho OR, Lafreniere-Roula M, Thorpe KE, Quan A, Leiter LA, Yan AT, Verma S. Empagliflozin and left ventricular remodeling in people without diabetes. Primary results of the EMPA-HEART 2 CardioLink-7 randomized clinical trial. Circulation. 2023 Jan 24;147(4):284-295.

View details on PubMed

Secondary Publications

Bakbak E, Verma S, Krishnaraj A, Quan A, Wang C-H, Pan Y, Puar P, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1210-H1222.

View details on PubMed

Mistry N, Verma S, Puar P, Verma R, Teoh H, Quan A, Yan AT, Wang C-H, Connelly KA, Mazer CD, EMPA-HEART investigators. A Patient-Level Pooled Analysis of Two Empagliflozin Trials on Left Ventricular Remodeling. J Card Fail. 2023 Aug;29(8):1218-1221.

View details on PubMed

Empagliflozin and Cardiac Remodelling in People Without DiabetesThe EMPA-HEART 2 CardioLink-7 Trial

Empagliflozin and Cardiac Remodelling in People Without Diabetes
The EMPA-HEART 2 CardioLink-7 Trial